Navigation Links
National Minority Quality Forum Creates Advanced, Precision Tracking Tool to Address Prevalence of Peripheral Arterial Disease
Date:9/15/2009

toms include leg pain when walking and wounds that are slow to heal. P.A.D. can also lead to disability, amputation, and poor quality of life.

Researchers, patient advocacy groups, legislators and allied health professionals can use the

P.A.D. Atlas to identify prevalence of P.A.D. at the national, state, and local levels to direct educational resources where they are needed most.

"The launch of the P.A.D. Atlas is of great significance, especially to the racial and ethnic minority community. Being able to identify P.A.D prevalence among constituents is extremely useful to reduce preventable illness and will help raise awareness of and address health disparities in these underserved populations," said Rep. Donna M. Christensen (D-VI).

"We are proud to partner with the P.A.D. Coalition and their membership of committed partners on this very important initiative. Special thanks to the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership for their visionary leadership, their commitment to ending health disparities among the underserved and for their support in helping to make the P.A.D. Atlas initiative a reality," said Gary Puckrein, CEO, NMQF.

About the National Minority Quality Forum

Gary A. Puckrein, PhD, President and Chief Executive Officer of the National Minority Quality Forum founded the organization in 1998 to address the critical need for strengthening national and local efforts to use evidence-based, data-driven initiatives to guide programs to eliminate the disproportionate burden of premature death and preventable illness for racial and ethnic minorities and other special populations. The Forum has introduced disease atlases for chronic kidney disease, diabetes, heart disease, and HIV/AIDS.

Since 2004, the Forum has hosted the Annual Leadership Summit in April, focusing on disparities and improving quality of health care for all
'/>"/>

SOURCE National Minority Quality Forum
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. 21st International Radon Symposium
2. Olympus Managed Health Care Nominated for Prestigious International Award
3. Hard Rock International Marks 10 Years Of Support For Breast Cancer Awareness And Research With 2009 PINKTOBER(TM) Campaign Featuring Melissa Etheridge, The Bangles, Melanie C, Joss Stone And More
4. CPF Holds Seventh Annual National Pulmonary Fibrosis Awareness Week
5. National Certification for Medical Interpreters - Public Call for Final Written Pilot Exam
6. Latino HIV/AIDS Crisis Demands Attention - Health Care Professionals from Across the United States Gather in New York City for National Conference on Latinos and AIDS to Address Concerns
7. Project Lifesaver International Receives Federal Assistance for the Missing Alzheimers Patient Assistance Program
8. Bupa Launches its 2009 International Charity Challenge to Help a Rural Community in Ecuador
9. Third National Annual Salary Survey for Medical Interpreters Underway
10. Prodigy Again Teams Up with National Federation of the Blind at N.C. Convention
11. PRA International Chairs Session on Post Marketing Safety Issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... along with the Japanese government and the Bill ... bolster Japan,s contribution to global health through the ... a press conference held as a side event ... Development (TICAD V). , Representatives from each of ... Labour and Welfare, the Ministry of Foreign Affairs, ...
(Date:6/19/2013)... Dental professionals are increasingly monitoring end tidal carbon ... sedation, a patient’s breathing depth and rate decrease. ... to update its guidelines to require etCO2 monitoring, or ... to increase safety in procedures. This amendment to Section ... effect July 1. , The Oregon Board of ...
(Date:6/19/2013)... Ariz. (PRWEB) June 19, 2013 PREFERRED ... WellCare of Arizona to offer a new ... Maricopa, Pima, La Paz, Yavapai and Mohave, Arizona counties. ... Mohave counties were effective January 1, 2013 and Maricopa ... 2014. , WellCare, Inc., the parent company of WellCare ...
(Date:6/19/2013)... Brightree LLC , the leading provider of cloud-based ... care industry, has been ranked for the first time - ... (HCI 100) list. This prestigious list features the top ... revenue during the last fiscal year. Since 2005, Brightree’s revenue ... the company has built its organization to more than 500 ...
(Date:6/19/2013)... Guests at the Residence Inn Scottsdale Paradise Valley ... go to bed or rise early thanks to a new ... , Crafty travelers will have a little extra change in ... Paradise Valley hotel’s Book Early and Save Up to ... notice, guests can enjoy the year-round Scottsdale sunshine in deluxe ...
Breaking Medicine News(10 mins):Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4
... of the BBVA Foundation, Francisco Gonzlez, Jose Baselga, ... Center (MGHCC), and Andrs de Kelety, Managing Director ... in Barcelona, yesterday signed the agreement creating the ... the event was the Foundation,s Director, Mr. Rafael ...
... (HealthDay News) -- Women and younger men account for a ... are less likely than older men to receive preventive medications ... Researchers evaluated more than 3,000 heart attack patients treated at ... and found that 70.3 percent of them had not been ...
... study to investigate the tolerability of the breast cancer drug ... stop taking their prescribed therapy early because of problems with ... of the research paper, published today in the cancer journal ... 64 male breast cancer patients at their institution who had ...
... rely on recombinant, protein-based drugs must often endure ... intravenous therapy. Researchers at Children,s Hospital Boston demonstrate ... engineered cells, could secrete the drug on demand ... issue of the journal Blood , they ...
... By Randy Dotinga HealthDay Reporter , TUESDAY, ... whole-body vibration doesn,t appear to improve the bone health ... osteoporosis. The treatment -- which involves standing on a ... -- showed promise in animals. But researchers, who hoped those ...
... read will be one of the topics of a conference ... co-sponsored by the UC Davis Center for Mind and Brain, ... Visual Learning, and the departments of psychology and linguistics at ... to read, said David Corina, professor in the Department of ...
Cached Medicine News:Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 2Health News:Mass. General Cancer Center and Vall d'Hebron Institute of Oncology biomarker alliance 3Health News:Women, Younger Men Under-Treated Before Heart Attack: Study 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 3Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 2Health News:Engineered, drug-secreting blood vessels reverse anemia in mice 3Health News:Whole-Body Vibration Doesn't Build Bone After All: Study 2Health News:Visual language, cognition and deaf education topics of summit 2
(Date:6/19/2013)... , June 19, 2013   Voices Against ... finding a cure for brain cancer, today announced that ... grant to support the clinical investigation of Toca 511 ... high grade glioma brain cancer (Grade 3 or Grade ... novel treatments for advanced cancer, with an initial focus ...
(Date:6/19/2013)... DIEGO , June 19, 2013   Nektar Therapeutics ... results from a human abuse liability (HAL) study for ... rate of entry into the brain.  This slow rate of ... to the abuse of and addiction to current opioid analgesics. ... NKTR-181 was rated similar to placebo in "drug liking" ...
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
... Varian Medical Systems (NYSE: VAR ) ... U.S. Customs and Border Protection (CBP) for multiple IntellX® cargo ... company,s largest single order for Varian,s IntellX gantry systems. The ... vehicles for both border security and manifest verification purposes. ...
... 2011 DURECT Corporation (Nasdaq: DRRX ) ... (FDA) has accepted the resubmission of the New Drug ... KG ) and the PDUFA goal date ... ) REMOXY, based on DURECT,s ORADUR® technology, ...
Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 3
... the right features for assay development ... instrument control. Reduces the inevitable transfer ... HTS. Specifically developed to meet the ... AD delivers unparalleled detection performance for ...
... The POLARstar OPTIMA is a fully ... incorporates five different measurement principles:, , ... , Time-Resolved Fluorescence , High-Performance ... Absorbance ,It is designed ...
... of PCR, cDNA and Oligonucleotides The ... for a variety applications that are quantified by ... to handle assays in Microplate formats from ... Cuvettes Independent whether you have ...
The basic modular Wallac 1420 VICTOR2 is a manually operated platereader which enables luminometry, fluorometry and photometry measurements to be made....
Medicine Products: